|View printer-friendly version|
ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting
Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed by ASLAN across multiple indications including a global pivotal trial in biliary tract cancer and a global study in gastric cancer.
Details of the posters presented are as follows:
Poster title: Multicenter Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.
Poster title: JADETREE: A phase 2A, single arm, multicentre study of varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC).
Copies of the posters are available to view and download from ASLAN Pharmaceuticals’ website.
Media and IR contacts
About varlitinib (ASLAN001)
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited